Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: drug profile and expert opinion on the prevention and management of adverse events
Derenzini, E. Gibb, A. Kwiatek, M. Strati, P.
Derenzini, E.
Gibb, A.
Kwiatek, M.
Strati, P.
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma in the United States and Western Europe and patients with relapsed or refractory (R/R) DLBCL who do not respond to salvage therapies have a poor prognosis. Loncastuximab tesirine (loncastuximab), a CD19-directed antibody-drug (pyrrolobenzodiazepine, PBD) conjugate approved as single agent for the third-line treatment of adult patients with R/R DLBCL and high-grade B-cell lymphoma, has shown durable clinical antitumor activity, including in difficult-to-treat subgroups. While loncastuximab has an overall manageable safety profile, it may cause drug-specific adverse events (AEs) different from other R/R DLBCL treatments. After summarizing the profile of loncastuximab, here we discuss PBD-specific AEs such as phototoxicity & cutaneous reactions, edema & effusions, and liver enzyme elevation; and use available clinical trial data, real-world evidence and clinical scenarios to provide expert opinion and practical advice on how to prevent and manage these non-hematological, PBD-specific AEs.
Authors
Description
Date
2025
Publisher
Collections
Keywords
Type
Article
Citation
Derenzini E, Gibb A, Kwiatek M, Strati P. Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: drug profile and expert opinion on the prevention and management of adverse events. Leuk Lymphoma. 2025 Jun 30:1-13. PubMed PMID: 40588166. Epub 2025/07/01. eng.